The ESMO Translational Research Working Group was formed to promote high-quality translational research in oncology and to develop translational research-related content for the Society's educational programmes.
in 2012, the ESMO Executive Board established the Personalised Medicine Task Force to steer ESMO's scientific and educational strategy and to monitor policy-oriented initiatives in personalised medicine at EU level.
In 2014, the ESMO Translational Research Working Group and the ESMO Personalised Medicine Task Force became a single group. With such a merge, ESMO aims to optimise the activities in these two related fields and maximise targeted education on translating cancer discoveries into clinical practice setting.
Activities and responsibilities
- Serve as a resource to ESMO in developing and reviewing in depth scientific and educational activities in translational research and personalised medicine for oncologists to improve patient care
- Serve as a resource to ESMO in promoting/supporting career in translational research and personalised cancer medicine
- Serve as the resource to ESMO in developing content of translational research and personalised cancer medicine messages for delivery through different Society channels
- Serve as the resource to ESMO in analysing cancer research regulatory activities and development of strategies in removing/minimising barriers for incorporation of translational components into clinical research projects
- Serve as the resource to ESMO on positioning the medical oncology profession in striving for realistic and achievable initiatives to support accelerated adoption of personalised cancer medicine
- Joaquin Mateo, Spain
- Fabrice André, France
- Frédéric Bibeau, France
- Giuseppe Curigliano, Italy
- Leticia De Mattos-Arruda, Spain
- Andrew Furness, UK
- Rowan Miller, UK
- Jorge Reis-Filho, US
- Joan Seoane, Spain
- Noelia Tarazona, Spain
- Benedict Westphalen, Germany
Last update: March 2021